Aribio announced on September 4 that the results of its joint clinical study on hyaluronic acid filler with the Department of Dermatology at Seoul National University Bundang Hospital have been published in the latest issue of PRS (Plastic and Reconstructive Surgery), an international journal in the field of plastic and reconstructive surgery.
PRS is the official journal published by the American Society of Plastic Surgeons. It is considered one of the most influential journals among researchers and clinicians worldwide in the fields of plastic and reconstructive surgery. The published paper details the verification of the efficacy and safety of the hyaluronic acid filler co-developed by Aribio and the research team led by Professors Heo Changhun, Shin Jeongwon, and Kim Bori from the Department of Dermatology at Seoul National University Bundang Hospital.
The company and the research team evaluated the nasolabial fold improvement effect over 24 weeks. Using a randomized, double-blind method, they administered the Aribio filler and Allergan's Juvederm filler, respectively. Both the Wrinkle Severity Rating Scale (WSRS) and the Global Aesthetic Improvement Scale (GAIS) met the non-inferiority criteria, demonstrating sustained wrinkle improvement and high aesthetic satisfaction.
Professor Heo stated, "The safety of hyaluronic acid fillers used in clinical practice is a critical issue," adding, "The new product confirmed in this study showed fewer side effects, such as swelling, compared to the control group, while providing equivalent efficacy."
Based on these results, Aribio plans to actively target global markets, including Europe, North and South America, and Southeast Asia. The company is currently preparing to obtain CE certification for Europe and Medical Device Single Audit Program (MDSAP) certification through its production facilities, which are already certified for Good Manufacturing Practice (GMP) and the international standard for medical device quality management systems (ISO13485).
Seo Boseung, Head of Aribio Medical Device Research Institute, said, "Aribio has continued investment and research in the anti-aging and biomedical sectors for over 10 years, including the development of the oral dementia treatment AR1001," adding, "We will begin full-scale exports of high-value-added medical device products, including high-performance fillers, based on our accumulated technological capabilities."
Meanwhile, Aribio is currently pursuing a merger with Solux.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
